Structure - Activity relationship studies of targeting ligands against breast cancer cells

Nianhuan Yao, Wenwu Xiao, Leah Meza, Harry Tseng, Mathida Chuck, Kit Lam

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

A series of LXY3 (1) analogues were designed and synthesized. Their binding affinity was demonstrated using MDA-MB-231 breast cancer cells adherence inhibition assay. Further structure-activity relationship was obtained. Analogue 29 was discovered to have 3.5-fold increase of the binding affinity. Fluorescent microscopy and in vivo and ex vivo imaging studies demonstrated that 29 is an efficient in vivo targeting agent against α3 integrin of MDA-MB-231 breast tumor xenograft implant.

Original languageEnglish (US)
Pages (from-to)6744-6751
Number of pages8
JournalJournal of Medicinal Chemistry
Volume52
Issue number21
DOIs
StatePublished - Nov 12 2009

Fingerprint

Structure-Activity Relationship
Breast Neoplasms
Ligands
Heterografts
Integrins
Intravital Microscopy

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Structure - Activity relationship studies of targeting ligands against breast cancer cells. / Yao, Nianhuan; Xiao, Wenwu; Meza, Leah; Tseng, Harry; Chuck, Mathida; Lam, Kit.

In: Journal of Medicinal Chemistry, Vol. 52, No. 21, 12.11.2009, p. 6744-6751.

Research output: Contribution to journalArticle

Yao, Nianhuan ; Xiao, Wenwu ; Meza, Leah ; Tseng, Harry ; Chuck, Mathida ; Lam, Kit. / Structure - Activity relationship studies of targeting ligands against breast cancer cells. In: Journal of Medicinal Chemistry. 2009 ; Vol. 52, No. 21. pp. 6744-6751.
@article{f672799a9f5e486d9716d4cc8687ac97,
title = "Structure - Activity relationship studies of targeting ligands against breast cancer cells",
abstract = "A series of LXY3 (1) analogues were designed and synthesized. Their binding affinity was demonstrated using MDA-MB-231 breast cancer cells adherence inhibition assay. Further structure-activity relationship was obtained. Analogue 29 was discovered to have 3.5-fold increase of the binding affinity. Fluorescent microscopy and in vivo and ex vivo imaging studies demonstrated that 29 is an efficient in vivo targeting agent against α3 integrin of MDA-MB-231 breast tumor xenograft implant.",
author = "Nianhuan Yao and Wenwu Xiao and Leah Meza and Harry Tseng and Mathida Chuck and Kit Lam",
year = "2009",
month = "11",
day = "12",
doi = "10.1021/jm9012032",
language = "English (US)",
volume = "52",
pages = "6744--6751",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "21",

}

TY - JOUR

T1 - Structure - Activity relationship studies of targeting ligands against breast cancer cells

AU - Yao, Nianhuan

AU - Xiao, Wenwu

AU - Meza, Leah

AU - Tseng, Harry

AU - Chuck, Mathida

AU - Lam, Kit

PY - 2009/11/12

Y1 - 2009/11/12

N2 - A series of LXY3 (1) analogues were designed and synthesized. Their binding affinity was demonstrated using MDA-MB-231 breast cancer cells adherence inhibition assay. Further structure-activity relationship was obtained. Analogue 29 was discovered to have 3.5-fold increase of the binding affinity. Fluorescent microscopy and in vivo and ex vivo imaging studies demonstrated that 29 is an efficient in vivo targeting agent against α3 integrin of MDA-MB-231 breast tumor xenograft implant.

AB - A series of LXY3 (1) analogues were designed and synthesized. Their binding affinity was demonstrated using MDA-MB-231 breast cancer cells adherence inhibition assay. Further structure-activity relationship was obtained. Analogue 29 was discovered to have 3.5-fold increase of the binding affinity. Fluorescent microscopy and in vivo and ex vivo imaging studies demonstrated that 29 is an efficient in vivo targeting agent against α3 integrin of MDA-MB-231 breast tumor xenograft implant.

UR - http://www.scopus.com/inward/record.url?scp=71049195364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71049195364&partnerID=8YFLogxK

U2 - 10.1021/jm9012032

DO - 10.1021/jm9012032

M3 - Article

VL - 52

SP - 6744

EP - 6751

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 21

ER -